Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Early Parkinson Disease Clear all
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

NCT00909545
View directory record Official record
Conditions
Parkinson Disease
Interventions
Isradipine CR 5mg, Isradipine CR 10mg, Isradipine CR 20mg, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Sunnyvale, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jun 10, 2026, 10:18 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

NCT05418673
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486
View directory record Official record
Conditions
Parkinson Disease
Interventions
NS 2330
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Blood Biomarker in Early Parkinson's Disease

NCT03384797
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

NCT02807675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, LIP, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

NCT05348785
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Terminated No phase listed Observational

Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)

NCT03716258
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jun 10, 2026, 10:18 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Early Parkinson's Disease (PD) Cross-Sectional

NCT00817453
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional Results available

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186
View directory record Official record
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

NCT04524351
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease
Interventions
Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jun 10, 2026, 10:18 PM EDT
Terminated Phase 2 Interventional Results available

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

NCT02906020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
venglustat GZ/SAR402671, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Assessments in the Clinic and Home in PD

NCT03681015
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
17
States / cities
Sun City, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Jun 10, 2026, 10:18 PM EDT
Recruiting Phase 2 Interventional

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

NCT07265596
View directory record Official record
Conditions
Prodromal Parkinsons Disease
Interventions
[18F] AV-133 PET Imaging
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 10, 2026, 10:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

NCT03043768
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
GWT-TUD GmbH
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jun 10, 2026, 10:18 PM EDT
Not listed Phase 1 Interventional

Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD)

NCT04922190
View directory record Official record
Conditions
Parkinson Disease
Interventions
Physical Activity Coaching
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2009 · Synced Jun 10, 2026, 10:18 PM EDT
Not listed Phase 2 Interventional

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

NCT01560754
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine transdermal patch
Drug
Lead sponsor
James BOYD MD
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Sunnyvale, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial

NCT00063193
View directory record Official record
Conditions
Parkinson's Disease
Interventions
minocycline, creatine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

NCT00058838
View directory record Official record
Conditions
Parkinson Disease
Interventions
sumanirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2006 · Synced Jun 10, 2026, 10:18 PM EDT
Completed Phase 2 Interventional

Phase 2a Study of VTX3232 in Parkinson's Disease

NCT06556173
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
VTX3232
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 10:18 PM EDT